Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's ...

Shares of Pfizer (NYSE: PFE) have been stuck in the mud since December 2022, with its shares down more than 45% over that ...

Since 2011, Starboard Value's Jeff Smith has extracted board seats and profits from corporate America — by force if necessary ...

Activist investor Starboard Value is looking to shake up pharma giant Pfizer's sagging stock price.

Leerink Partners analyst David Risinger has maintained their neutral stance on PFE stock, giving a Hold rating yesterday. David Risinger has ...

Pfizer Inc. CEO Albert Bourla is set to meet with activist investor Starboard Value amid growing pressure to revitalize the ...

J.P. Morgan analyst Chris Schott maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $30.00. The ...

Pfizer CEO is set to meet with activist investor Starboard Value after the investor acquired a $1 billion stake in the ...

(Reuters) - U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age ...

Pfizer sold a stake in British consumer healthcare group Haleon worth about $3.26 billion on Monday, cutting its shareholding ...

Citing people familiar with the matter, The Journal reported that Starboard approached former Pfizer CEO Ian Read and CFO ...

Although it has been plagued by multiple issues, including falling sales with lower demand for its Covid-19 products, and an ...